CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Q1 2023 Earnings Call Transcript

Operator: Good day, ladies and gentlemen, and welcome to CymaBay’s First Quarter 2023 Financial Results and Business Update Conference Call. At this time, all participants are in a listen-only mode.

Related Keywords

Toronto ,Ontario ,Canada ,Vienna ,Wien ,Austria ,Zurich ,Züsz ,Switzerland ,Sujal Shah ,Kristen Kluska ,Harish Shantharam ,Jay Olson ,Andy Hsieh ,Patrick Dolezal ,Lewis Stuart ,Charles Mcwherter ,Raymond James ,Yasmeen Rahimi ,Paul Quinlan ,Ed Arce ,Mayank Mamtani ,Piper Sandler ,Steve Seedhouse ,Chuck Mcwherter ,William Blair ,Andreas Kremer ,Julian Harrison ,Gideon Hirschfield ,Dan Menold ,University Of Zurich ,Cymabay Therapeutics Inc ,Cantor Fitzgerald ,University Of Toronto Liver Center ,Amgen ,Japan To Kaken Pharmaceutical Company ,Nasdaq ,Gilead Sciences ,Cymabay Therapeutics ,Call Transcript May ,Bay Therapeutics ,First Quarter ,Business Update Conference ,General Counsel ,Chief Executive Officer ,Chief Scientific Officer ,Chief Commercial Officer ,Private Securities Litigation Reform Act ,Kaken Pharmaceutical Company ,Chief Financial ,Vice President ,Global Commercial ,Safety Monitoring Board ,Professor Andreas Kremer ,Professor Gideon Hirschfield ,Toronto Liver Center ,Baseline Characteristics ,Risk Profiles ,Novel Pathways ,